Compare Essex Property Trust, Inc. (ESS) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Incyte Corporation — how do they compare? Essex Property Trust, Inc. trades at $282.11 (market cap $18.15B), while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: Incyte Corporation is the larger of the two by market cap, and Essex Property Trust, Inc. pays a 3.93% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| ESS | INCY | |
|---|---|---|
Market Cap | $18.15B | $24.54B |
Sector | Real Estate | Health |
52-Week High | $298.33 | $129.93 |
52-Week Low | $239.61 | $81.61 |
Enterprise Value | $24.75B | $20.04B |
Dividend Yield | 3.93% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
